Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Stopped early · Phase 1
Conditions studied: Leukemia
In brief
RATIONALE: Drugs used in chemotherapy, such as cytarabine, daunorubicin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with tipifarnib may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of tipifarnib when given together with combination chemotherapy in treating patients with newly diagnosed acute myeloid leukemia.
Key facts
- Study ID
- NCT00124644
- Run by
- Ohio State University Comprehensive Cancer Center
- People needed
- 30
- Starts
- 2006-03-01
- Expected to finish
- 2008-01-01
- Last updated by the study team
- 2013-05-03
Who can join
Age: 18 and older, up to 59. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center — Columbus, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.